Lantern Pharma

Yahoo Finance • 20 days ago

New to The Street Announces Broadcast of Show #739 on Bloomberg Television Across the U.S. at 6:30 PM EST

Featured Companies Include FreeCast (NASDAQ:CAST), KLED.ai, Lantern Pharma (NASDAQ:LTRN), and BlackBarn Restaurant NEW YORK CITY, NY / ACCESS Newswire / March 21, 2026 / New to The Street, one of the longest-running U.S. and international... Full story

Yahoo Finance • 2 months ago

Lantern Pharma (LTRN) Advances Oncology AI and Gains Orphan Drug Recognition

Lantern Pharma, Inc. (NASDAQ:LTRN) is one of the best AI penny stocks to buy right now. On January 20, the FDA granted Lantern Pharma, Inc.’s (NASDAQ:LTRN) LP-284 an Orphan Drug Designation (ODD). LP-284 is an investigational small-molecul... Full story

Yahoo Finance • 7 months ago

Lantern Pharma Says Phase 1a Study Of LP-184 Met All Primary Endpoints In Advanced Solid Tumors

(RTTNews) - Lantern Pharma Inc. (LTRN) announced Tuesday that its Phase 1a study evaluating the drug candidate LP-184 in patients with advanced solid tumors, including Glioblastoma Multiforme (GBM), an aggressive form of brain cancer, met... Full story

Yahoo Finance • 7 months ago

IBN Announces Latest Episode of The BioMedWire Podcast Featuring Panna Sharma, CEO of AI-Driven Biotech Focused on Challenging & Rare Cancers, Lantern Pharma Inc. (LTRN)

AUSTIN, Texas, Sept. 10, 2025 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of T... Full story

Yahoo Finance • 8 months ago

Lantern Pharma completes Japanese enrollment in lung cancer trial

DALLAS - Lantern Pharma Inc. (NASDAQ:LTRN), a clinical-stage biotech company currently trading at $4.01, has completed patient enrollment for its Phase 2 HARMONIC clinical trial in Japan ahead of schedule, the company announced Thursday in... Full story

Yahoo Finance • 8 months ago

Lantern Pharma appoints Lee T. Schalop, M.D. to board and amends quorum rules

Lantern Pharma Inc . (NASDAQ:LTRN) announced that its board of directors appointed Lee T. Schalop, M.D. to the board, effective Thursday. The appointment was made following a recommendation from the board’s Nominating and Corporate Governa... Full story

Yahoo Finance • 8 months ago

Lantern Pharma appoints biotech executive Lee Schalop to board

DALLAS - Lantern Pharma Inc. (NASDAQ:LTRN), an AI-driven oncology drug development company with a current market capitalization of $45.67 million, announced Monday the appointment of Lee T. Schalop, MD, to its Board of Directors. The compa... Full story

Yahoo Finance • 9 months ago

Lantern Pharma reports complete response in aggressive lymphoma patient

DALLAS - Lantern Pharma Inc. (NASDAQ:LTRN), a $43.46 million market cap biotech company whose stock has gained 26.33% year-to-date, announced Wednesday that a patient with aggressive Grade 3 non-germinal center B-cell diffuse large B-cell... Full story

Yahoo Finance • 9 months ago

Lantern Pharma secures EU patent for AI-driven cancer drug LP-284

Lantern Pharma (NASDAQ:LTRN [https://seekingalpha.com/symbol/LTRN]) Monday said [https://seekingalpha.com/pr/20171807-lantern-pharma-secures-eu-patent-allowance-for-lpminus-284-bolstering-global-ip-position-for]that the European Patent Off... Full story

Yahoo Finance • 10 months ago

Lantern Pharma shares sold by major shareholder for $123,600

FORT WORTH, Texas— Lantern Pharma Inc . (NASDAQ:LTRN) witnessed a notable stock sale by a major shareholder, as disclosed in a recent SEC filing. The timing is particularly interesting as InvestingPro data shows the stock has declined over... Full story

Yahoo Finance • 3 years ago

Lantern Pharma said it had no exposure to SVB or Signature Bank, after stock plunged last week

Lantern Pharma Inc. (LTRN) confirmed Monday that it, or any of its subsidiaries, had no exposure to SIVB Financial Group’s (SIVB) Silicon Valley Bank, Silvergate Capital Corp. (SI) or Signature Bank (SBNY) The biopharmaceutical company’s s... Full story

Yahoo Finance • 3 years ago

FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in Mantle Cell Lymphoma

The Orphan Drug Designation strengthens LP-284’s clinical development path and provides the opportunity for additional market exclusivity and commercial protection. Lantern is anticipating filing the IND with the FDA and initiating a first... Full story

Yahoo Finance • 3 years ago

Lantern Pharma to Participate at the RHK Capital Disruptive Growth Conference on December 5 at 12:00 p.m. ET

DALLAS, Dec. 02, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- Lantern Pharma Inc (Nasdaq: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (“M.L.”) platfo... Full story

Yahoo Finance • 3 years ago

Lantern Pharma to Report Third Quarter 2022 Operating & Financial Results on November 7, 2022 at 4:30 p.m. ET

Webcast to be held Monday Nov. 7, 4:30 p.m. ET, register here. DALLAS, October 31, 2022--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (... Full story

Yahoo Finance • 3 years ago

Lantern Pharma to Present at the ThinkEquity Conference on Wednesday, October 26 at 1:00 p.m. ET

DALLAS, October 21, 2022--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning ("M.L.") platform to transform the... Full story

Yahoo Finance • 4 years ago

We're Not Very Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining exploration companies often lose money for years before finding success with a new treatment or mineral discovery. Nonetheless... Full story

Yahoo Finance • 4 years ago

Lantern Pharma Management to Speak at Multiple Investor and Scientific Conferences in May 2022

DALLAS, May 05, 2022--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (ML) platform to transform the cost, pa... Full story

Yahoo Finance • 4 years ago

Lantern Pharma to Report First Quarter 2022 Operating & Financial Results on May 3rd, 2022 at 4:30 p.m. ET

DALLAS, April 22, 2022 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (A.I.) and machine learning (ML) platform to transform the cost, pace... Full story